Table of contents
March 2008 Volume 5 No 3
Editorial
Why should we increase public awareness of bladder cancer, and how can we do it?
117doi:10.1038/ncpuro1061 | Full Text | PDF (134K)
Viewpoints
Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neuromodulation
118This article is the first of two Viewpoints on the treatment of detrusor overactivity. The authors of this article advocate the use of sacral nerve modulation for this indication, and they describe the advantages of sacral nerve modulation compared with botulinum neurotoxin.
doi:10.1038/ncpuro1033 | Full Text | PDF (168K)
Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neurotoxin
120In this second Viewpoint on the treatment of detrusor overactivity, the authors describe the preclinical and clinical data that support the use of botulinum neurotoxin in patients with detrusor overactivity, and highlight the benefits of botulinum neurotoxin over the use of sacral nerve modulation.
doi:10.1038/ncpuro1034 | Full Text | PDF (175K)
Research Highlights
High fructose intake associated with increased risk of kidney stones
122Cholesterol-lowering drugs might reduce the risk of advanced prostate cancer
122Time concerns might underlie Korean men's preference for tadalafil over sildenafil
123Low-risk superficial bladder tumors: further observations on conservative management
123Rapid intraoperative tissue expansion can be used for scrotal reconstruction
124Good intermediate-term oncologic outcomes reported for RF-LPN
124TENS might be effective in children with treatment-refractory overactive bladder
125Serial treatment with antiangiogenic agents for patients with metastatic RCC
125Antiseptic lavage reduces infection of inflatable penile prostheses
125Urologist characteristics predict whether patients with prostate cancer receive ADT
126Adult male circumcision does not reduce sexual satisfaction and performance
126Hemodilution of PSA in obese men could delay diagnosis of prostate cancer
127Practice Points
Is solifenacin succinate safe and effective for the treatment of overactive bladder?
128doi:10.1038/ncpuro1040 | Full Text | PDF (172K)
Why do men who receive finasteride have an increased prevalence of high-grade prostate cancer?
130doi:10.1038/ncpuro1041 | Full Text | PDF (174K)
Is sorafenib plus interferon 
2b safe and effective in patients with renal cell carcinoma?
132doi:10.1038/ncpuro1036 | Full Text | PDF (178K)
What is the optimum PSA screening interval after an initial negative test?
134doi:10.1038/ncpuro1038 | Full Text | PDF (174K)
Is salvage cryoablation effective in patients with prostate cancer who have failed radiation therapy?
136doi:10.1038/ncpuro1039 | Full Text | PDF (174K)
A nomogram for predicting 10-year life expectancy in men with prostate cancer after definitive therapy
138doi:10.1038/ncpuro1037 | Full Text | PDF (169K)
Reviews
Safety of assisted reproduction, assessed by risk of abnormalities in children born after use of in vitro fertilization techniques
140Despite being used in practice for around 30 years, the safety of assisted reproductive technologies is still questioned. Studies are hampered by issues related to trial design and consistency of reporting. Some long-term data are, however, now available for offspring conceived after assistance by a variety of technologies. This Review aims to summarize the reported risks.
doi:10.1038/ncpuro1045 | Full Text | PDF (598K)
Donor insemination and infertility: what general urologists need to know
151Advances in assisted reproductive technologies have led to declining use of therapeutic donor insemination by urologists treating male factor infertility. Insemination by this technique is, however, still appropriate for a notable number of couples trying to conceive. This Review discusses the indications and the related outcomes, costs and psychosocial issues.
doi:10.1038/ncpuro1018 | Full Text | PDF (318K)
Persistent prostatic hematuria
159Recurrent prostatic bleeding can be challenging and frustrating for physicians and patients. Sepsis and bladder rupture are notable complications of therapy in severe cases, and more-serious, possibly fatal, events can occur in patients with comorbidities. An overview of causes and a guide to management with biochemical and functional approaches is provided.
doi:10.1038/ncpuro1044 | Full Text | PDF (390K)
Case Study
A case of primary lymphoma of the bladder managed with multimodal therapy
167Primary lymphoma of the bladder is a rare condition, typically presenting as intermittent hematuria, urinary frequency and dysuria. In this Case Study, Horasanli et al. report the management, using transurethral resection, chemotherapy and radiotherapy, of a 65-year-old woman who presented with urinary symptoms and a right hydronephrosis resulting from this tumor.
doi:10.1038/ncpuro1035 | Full Text | PDF (343K)
